XNSE
ERIS
Market cap2.26bUSD
Nov 12, Last price
1,575.20INR
Name
Eris Lifesciences Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
Related entities
Subsidiaries (3)
ERIS HEALTHCARE PRIVATE LIMITED
ERIS OAKNET HEALTHCARE PRIVATE LIMITED
SWISS PARENTERALS LIMITED
Key people
Sachin Shah
Chief Financial Officer · since 2016
Amit Bakshi
Executive Chairman of the Board, Managing Director · since 2023
Inderjeet Negi
Executive Director · since 2016
Kaushal Shah
Executive Director · since 2020
Krishnakumar Vaidyanathan
Chief Operating Officer, Executive Director · since 2020
Milind Talegaonkar
Compliance Officer, Company Secretary · since 2016
Prashant Gupta
Non-Executive Independent Director · since 2018
Kalpana Unadkat
Non-Executive Independent Director · since 2021
Sujesh Vasudevan
Non-Executive Independent Director · since 2022
Legal address
SHIVARTH AMBIT, PLOT NO 142/2,
RAMDAS ROAD OFF SBR
NEAR SWATI BUNGALOWS, BODAKDEV
AHMEDABAD, GJ 380054
IN
RAMDAS ROAD OFF SBR
NEAR SWATI BUNGALOWS, BODAKDEV
AHMEDABAD, GJ 380054
IN
Headquarters
8TH FLOOR, COMMERCE HOUSE- IV, PRAHLADNAGAR
100 FT ROAD
AHMEDABAD, GJ 380015
IN
100 FT ROAD
AHMEDABAD, GJ 380015
IN
Valuation
Title INR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||